In late January 2010 the FDA approved Novo Nordisk’s newest medication, Victoza® (liraglutide), which is the first Glucagon Like Peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes mellitus. Unlike Byetta® (exenatide), the only other medication currently available in the GLP-1 receptor agonist class and a GLP-1 mimetic, Victoza® is 97% homologous with natural GLP-1 and is produced by recombinant DNA technology.